Form 4: Fortress Biotech Exits Checkpoint Therapeutics Holdings Following Sun Pharma Merger

Fortress Biotech, Inc. has reported the complete disposition of its equity stake in Checkpoint Therapeutics, Inc. as a result of Checkpoint's acquisition by Sun Pharmaceutical Industries, Inc. for $4.10 per share in cash plus a contingent value right.

Summary

• Fortress Biotech, Inc., a 10% owner and director of Checkpoint Therapeutics, Inc. (CKPT), reported the full disposition of its beneficial ownership in CKPT.
• On May 29, 2025, Fortress Biotech disposed of 100,000 shares of Checkpoint Therapeutics common stock at an exercise price of $1.29 per share. This transaction occurred due to the exercise of warrants by Lindsay A. Rosenwald and Michael S. Weiss, which were originally issued by Fortress Biotech from its holdings in Checkpoint Therapeutics. These warrants, initially for 500,000 shares, adjusted to 100,000 shares after a December 2022 reverse stock split.
• On May 30, 2025, Fortress Biotech disposed of its remaining 6,122,249 shares of common stock and 700,000 shares of Class A common stock in Checkpoint Therapeutics, both at a price of $4.10 per share.
• This final disposition was a direct result of the merger between Checkpoint Therapeutics and Snoopy Merger Sub, Inc., a wholly-owned subsidiary of Sun Pharmaceutical Industries, Inc., which closed on May 30, 2025.
• As per the merger agreement, each outstanding share of Checkpoint Therapeutics common stock and Class A common stock was converted into the right to receive $4.10 in cash, without interest, and one non-tradable contingent value right (CVR) representing the right to receive up to an additional $0.70 upon the achievement of a specified milestone.

Sentiment

Score: 7

Explanation: The sentiment is positive for Fortress Biotech as it successfully exited its investment in Checkpoint Therapeutics through a merger, realizing cash proceeds and retaining potential upside via a CVR. For Checkpoint Therapeutics, it signifies a successful acquisition by a larger entity.

Positives

• Fortress Biotech successfully monetized its investment in Checkpoint Therapeutics through the merger, receiving cash proceeds for its shares.
• The merger consideration includes a non-tradable Contingent Value Right (CVR) of up to $0.70 per share, offering potential additional upside if a specific milestone is achieved.

Negatives

• Fortress Biotech no longer holds any equity interest in Checkpoint Therapeutics, thereby losing direct participation in any future growth or success of the company.
• The Contingent Value Right (CVR) is non-tradable, which limits liquidity and the ability to realize its value before the milestone is met or not met.

Risks

• The contingent cash payment of up to $0.70 per share from the CVR is not guaranteed and is dependent on the achievement of a specified milestone, which may not occur.

Future Outlook

The document primarily reports past transactions related to a completed merger and does not provide forward-looking statements or guidance from Checkpoint Therapeutics or Fortress Biotech beyond the contingent value right's potential payment.

Industry Context

This Form 4 filing reflects the finalization of the acquisition of Checkpoint Therapeutics by Sun Pharmaceutical Industries, Inc., a significant event in the biotechnology and pharmaceutical sector. Such mergers often indicate consolidation trends, where larger pharmaceutical companies acquire smaller biotech firms for their pipeline assets or market access. The inclusion of a CVR is a common mechanism in biotech M&A to bridge valuation gaps and incentivize the acquired company's team to achieve specific clinical or regulatory milestones.

Comparison to Industry Standards

• NA

Related Party Transactions

• Fortress Biotech, as a 10% owner and director, issued warrants to Lindsay A. Rosenwald and Michael S. Weiss (who are likely related parties or executives within Fortress Biotech or Checkpoint Therapeutics given the context of the Long Term Incentive Plan), which led to the disposition of 100,000 shares.

Stakeholder Impact

• Shareholders of Checkpoint Therapeutics: Received $4.10 in cash per share and a non-tradable CVR for up to $0.70, converting their equity into cash and a contingent right.
• Fortress Biotech (as a shareholder): Successfully exited its investment, realizing cash proceeds and potential future upside from the CVR.
• Sun Pharmaceutical Industries, Inc.: Successfully acquired Checkpoint Therapeutics, expanding its portfolio.

Next Steps

• Achievement and potential payment related to the contingent value right (CVR) milestone.

Key Dates

Keywords

Fortress Biotech, Checkpoint Therapeutics, CKPT, Sun Pharmaceutical Industries, Merger, Acquisition, SEC Form 4, Beneficial Ownership, Stock Disposition, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals